Search Results

First report of subcutaneous amivantamab demonstrates compelling clinical activity in recurrent or metastatic head and neck cancer, building on strength in colorectal cancer and EGFR-mutated lung cancer New analysis and recent U.S. FDA Fast Track designation underscore promise of first-in-class pasritamig for prostate cancer

This year’s award went to six teams who participated in the Global Health Challenge, which asked: How can we use technology to make good health and quality care more accessible for all?

Here’s an infographic breakdown of the company’s third-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes

• 2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* • 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 • Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump • Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirms full year adjusted EPS4 guidance of $10.85 at the midpoint, absorbing higher tax costs

The tissue-sparing approach achieved with INHANCE INTACT™ provides surgeons with enhanced joint visualization1 as shoulder replacements surge in the U.S., growing at a compound annual growth rate of 7.3% and projected to reach USD 2.54 billion by 20302